Psychedelic therapy shows promise in mid-stage study in treatment-resistant depression

Taking stock of the drug industry, from the lab to the medicine chest

July 1, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Psychedelic therapy shows promise in mid-stage study in treatment-resistant depression Beckley Psytech plans to advance BPL-003, a short-acting compound related to the compound DMT, into a Phase 3 clinical trial. By Meghana Keshavan STAT+ | RFK Jr. says he has a team working on changes to the vaccine injury compensation program Kennedy says he has assembled a team to work on a federal program aimed at compensating people who have been injured by vaccines. By Chelsea Cirruzzo STAT+ | Sage Therapeutics cuts most of its workforce following acquisition Maryland-based Supernus Pharmaceuticals said earlier this month that it would acquire Sage in a deal worth up to $795 million. By Marin Wolf — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser